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1. INTRODUCTION {#jcmm13528-sec-0001}
===============

Renal cell carcinoma (RCC) is a kind of highly heterogeneous tumours. Clear cell renal cell carcinoma (ccRCC) is the major histological subtype (\~80%). The incidence of RCC continued to rise over the past 2 decades.[1](#jcmm13528-bib-0001){ref-type="ref"} It is 2‐fold higher in men than in women. Surgical resection remains the main curative treatment. In the acknowledge of RCC therapy, it does not respond to radiotherapy and chemotherapy effectively, but responds to targeted therapies partially. Although the application of targeted therapies for RCC is promising, but there are many problems of these novel strategies.[2](#jcmm13528-bib-0002){ref-type="ref"} Little is known about the advancement of specific prognostic or risk molecular markers for RCC.

Recent genome‐wide association studies (GWAS) indicated that several loci mapped on 2p21, 2q22.3, 11q13.3, 12p11.23 and 12q24.31 were associated with RCC risk significantly.[3](#jcmm13528-bib-0003){ref-type="ref"}, [4](#jcmm13528-bib-0004){ref-type="ref"}, [5](#jcmm13528-bib-0005){ref-type="ref"} However, the genetic risk factor identified in Caucasian population is not so consistent with that in Asian population.[6](#jcmm13528-bib-0006){ref-type="ref"} The causal genetic factors for RCC are still unclear.

In our previous study, we have screened the differentiated genes between metastasis and primary ccRCC cells using cDNA microarray. Glutathione‐S‐transferase Mu3 (*GSTM3*), a *GSTM*‐class subunit, was identified as a notably down‐regulated gene. It both down‐regulated in metastatic vs primary ccRCC cells and primary ccRCC cells vs adjacent normal renal tissues.[7](#jcmm13528-bib-0007){ref-type="ref"} We also studied the tumour suppressor role of *GSTM3* in the progression of ccRCC and a polymorphism rs1332018 which was significantly associated with the postoperative prognosis of ccRCC.[8](#jcmm13528-bib-0008){ref-type="ref"}

In the current study, we report a novel SNP in ccRCC‐ rs1055259 in the 3′untranslated region (UTR) of *GSTM3* significantly reduced the ccRCC risk and influence the binding of miR‐556 to the 3′UTR of *GSTM3*. This might be the potential mechanism of rs1055259 impact the renal carcinoma risk.

2. MATERIALS AND METHODS {#jcmm13528-sec-0002}
========================

2.1. Study population and postoperative Follow‐up {#jcmm13528-sec-0003}
-------------------------------------------------

Consecutive ccRCC patients who received curative nephrectomy at Department of Urinary Surgery in Changzhou first people\'s hospital, Zhenjiang first people\'s hospital and the first affiliated hospital of Soochow university from May 2006 to November 2015. Healthy controls were randomly selected from people who received physical examination at Advanced Physical Examination Center in the first affiliated hospital of Soochow University. The demographics and clinical features of the ccRCC patients and controls involved in the study are listed in Table [1](#jcmm13528-tbl-0001){ref-type="table-wrap"}. Cases and controls were frequency matched on gender and healthy controls were older than patients. All the patients were pathologically confirmed and signed the informed consent. Follow‐up was performed via in person interview or telephone calls according to the standard epidemiologic procedure twice a year. The final date of follow‐up was 12 December 2015. All the protocols conformed to the 1975 Declaration of Helsinki and were approved by ethics committee of the first affiliated hospital of Soochow University.

###### 

Demographic and clinical features of the study subjects

  Characteristic    Case‐control study                   
  ----------------- -------------------- --------------- ------------
  Age (y)                                                
  Average (Range)   55.62 (20‐85)        60.97 (24‐93)   **\<.001**
  ≤40               41 (12.46)           32 (7.62)       --
  40‐60             179 (54.41)          206 (49.05)     --
  60‐80             102 (31.00)          123 (29.28)     --
  \>80              7 (2.13)             59 (14.05)      --
  Gender                                                 
  Male              226 (68.69)          286 (68.10)     .861
  Female            103 (31.31)          134 (31.90)     --
  Histology                                              
  Clear cell        329 (100%)           --              --
  Papillary         0 (0)                --              --
  Chromophobe       0 (0)                --              --
  AJCC stage                                             
  I                 247 (75.08)          --              --
  II                49 (14.89)           --              --
  III               23 (7.00)            --              --
  IV                10 (3.03)            --              --

AJCC, American Joint Committee on Cancer; RCC, renal cell carcinoma. The significant *P* value was shown in bold.
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2.2. Blood samples collection and ccRCC cells primary culture {#jcmm13528-sec-0004}
-------------------------------------------------------------

Ethylene diamine tetraacetic acid (EDTA) anticoagulated peripheral blood samples were collected from patients before nephrectomy and healthy controls. Genomic DNA was extracted using a RelaxGene Blood DNA System (TIANGEN biotech, Beijing, China) according to the manufacturer\'s instruction. The fresh surgical specimens of ccRCC from 17 patients were harvested and immediately immersed in ice‐cold PBS containing 1% penicillin/streptomycin and 0.5% glutamine (Beyotime, Shanghai, China). Primary cell culture was performed within 60 min after surgery as previously described.[7](#jcmm13528-bib-0007){ref-type="ref"} As a variation of phenotype might occur at higher passages, we chose the ccRCC cultures at the fourth passage for functional experiments.

2.3. SNP selecting and genotyping {#jcmm13528-sec-0005}
---------------------------------

We selected 5 SNPs by analysing *GSTM*3‐related Han Chinese data from 1000 Genome Project resources (<http://www.1000genomes>. org). The candidate SNPs should meet these criteria: (1) the minor allele frequency (MAF) \> 0.05; (2) *r* ^2^ \< .80 (Figure [1](#jcmm13528-fig-0001){ref-type="fig"}A); (3) at the 3′UTR of *GSTM3*. The significant SNP rs1055259 is located at a miR‐556 binding site, with predicted proximal transcriptional regulatory potential (<http://rsnp.psych.ac.cn/>) (<http://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/> snpfunc.cgi). rs1537236, rs3814309, rs1109138 and rs5776997 were also predicted as functional SNPs, which seated in other miRNA binding sites.

![The linkage disequilibrium (LD) plot of SNPs in *GSTM3* gene and representative MALDI‐TOF MS spectra of rs1055259. (A) Pairwise LD among 5 candidate SNPs of *GSTM3*. The r2 value is shown in each diamond. It indicates the pairwise correlation between SNPs. The colour scale ranges white to black reflect lower to higher r2 values. (B) Genotypes of rs1055259 are confirmed by plotting peak intensity (*y*‐axis) against mass (Da) (*x*‐axis). (a) MALDI‐TOF MS spectrum of a single peak at 7748.5 Da represents homozygous genotype of AA. (b) MALDI‐TOF MS spectrum of a single peak at 7667.0 Da indicates homozygous genotype of GG. (c) MALDI‐TOF MS spectrum of 2 peaks at 7748.5 Da and 7667.0 Da indicates heterozygous genotype of AG](JCMM-22-3005-g001){#jcmm13528-fig-0001}

All SNPs were genotyped using matrix‐assisted laser desorption ionization time‐of‐flight mass spectrometry (MALDI‐TOF MS) and analysed on the MassARRAY platform (Sequenom, San Diego, CA, USA). The MALDI‐TOF MS spectra of rs1055259 were shown in Figure [1](#jcmm13528-fig-0001){ref-type="fig"}B. Amplification and single‐base extension primers applied in multiple PCR were synthesized by Benegene (Benegene Biotechnology, Shanghai, China) (Table [2](#jcmm13528-tbl-0002){ref-type="table-wrap"}). The product of each sample was dispensed onto a 384‐format SpectroCHIP with the MassARRAY Nanodispenser RS 1000. Then, the MALDI‐TOF MS assay was performed on a MassARRAY Compact Analyzer. Genotype calling was conducted using MassARRAY RT software version 3.0. Data were analysed with MassARRAY Typer software 4.0.3. Genotyping quality was assessed by Sanger sequencing of \~10% randomly selected samples, yielding a 100% concordance.

###### 

Primers for PCR and single‐base extension reaction in MALDI‐TOF MS assay

  Gene (GSTM3) Loci   Chr:position   Forward primer[a](#jcmm13528-note-0003){ref-type="fn"}   Reverse primer[a](#jcmm13528-note-0003){ref-type="fn"}   Extension primer           Amplicon size (bp)
  ------------------- -------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------- --------------------
  rs1537236           1:109736350    linker‐GCCCATAGGCTGCTCTGC                                linker‐ GCCTTAGGAAAAGTTGTAG                              CACAAA GGAAAGATTT          121
  rs3814309           1:109734781    linker‐GTGGCAAAACATGGCA GTTG                             linker‐ CAGGGATACCCAGTGATGTC                             TTAGCACCTTCTGTCTG          78
  rs1109138           1:109735327    linker‐AGCTTCAAATTCCTGG GCTC                             linker‐ ACCCCTGTCTCCCAAAAATT                             GGACTATGCATGAGCAA          69
  rs1055259           1:109734239    linker‐AGTGACCATCCCAACTTTGG                              linker‐ CCATGGGGGTGCTAAAACCAC                            TTTAACCCAGCTCATTAT         119
  rs5776997           1:109736432    linker‐GGGGTAGGAGAAGTTT CTTT                             linker‐ TACTCCACAGGCAGAGCAG                              CTTTAAAGACGTAAAAAGAAAAAA   86

linker = 10‐mer linker ACGTTGGATG placed at 5′‐end of each primer.
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2.4. Bioinformatic prediction of candidate SNPs {#jcmm13528-sec-0006}
-----------------------------------------------

The SNP‐flanking region RNA was online analysed using RNAfold (<http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi>) and SNPfold (<http://ribosnitch.bio.unc.edu/Downloads/SNPfold/>). SNPs at the 3′UTR were predicted for putative miRNA binding site applying 3 algorithms: TargetScan (<http://targetscan.org/>), PicTar (<http://pictar.mdc>‐ berlin.de/) and miRBase (<http://www.mirbase.org/search.shtml>).

2.5. Quantitative real‐time PCR analysis of miR‐556 {#jcmm13528-sec-0007}
---------------------------------------------------

The expression level of miR‐556 was detected using RNA‐tailing and primer‐extension real‐time PCR according to the instructions of All‐in‐One miRNA Detection Kit (Fulengen, Guangzhou, China). miR‐556 forward primer: 5′‐AGAAGCAATTCTAGAAG‐3′; the reverse primer was miRNA universal adaptor PCR primer (Fulengen).

2.6. Luciferase reporter assay {#jcmm13528-sec-0008}
------------------------------

To evaluate the binding of miR‐556 to 3′UTR of *GSTM3*, 3 reporter constructs carrying 2 copies of rs1055259‐A allele, G allele or mutant sequences at the 3′UTR of luciferase gene were created. Firstly, three \~100‐bp DNA sequences centred at rs1055259 (A or G allele) or mutant sequence were synthesized; then, 2 tandem copies of these sequences were cloned into pGL‐3 Basic vector (Promega, Madison, WI, USA) using restriction enzyme sites‐Sal I and BamH I. The schematic diagram for vector construction is shown in Figure [2](#jcmm13528-fig-0002){ref-type="fig"}A. Day 1, 786‐O cells were seeded at 1 × 10^4^ cells/well in a 24‐well plate. Day 2, cells were transfected with 0.8 μg pGL‐3 Basic vectors (inserted with rs1055259‐ A allele, G allele or mutant sequences) and 0.16 μg pRL‐TK vector (Luciferase Assay System; Promega). Cells were transfected with mimic control, inhibitor control, miR‐556 or antagomir miR‐556 (GenePharma, Shanghai) in different group. Day 3, the luciferase activity of cells was examined on Synergy H1 microplate reader (BioTek Instruments, Winooski, VT, USA) using Dual‐luciferase Reporter Assay System (Promega) according to the instruction of manufactures. Results were represented as relative luciferase activity to pRL‐TK.

![SNP rs1055259 affects luciferase activities in 786‐O cells. (A) Reporter plasmids construct. The schematic diagrams show the luciferase reporters carrying 2 copies of rs1055259‐A allele or G allele or mutant sequence at the 3′UTR of Luciferase gene. (B) This plot shows the theoretical miRNA‐mRNA duplex pairing between miR‐556 and *GSTM3* 3′UTR. The A, G alleles and mutant sequence are highlighted with an asterisk (\*). (C, D) Relative luciferase activities (vs Renila luciferase) were measured in ccRCC cells expressing either A allele, G allele or mutant construct which were treated with control miR, miR‐556 mimic or antagomir‐miR‐556. (E) After incubated with 50 μmol/L CoCl2 for 24 h, luciferase activities were examined in cells transfected with either A allele, G allele or mutant construct. Six replicates for each group and the experiment were repeated at least 3 times. \**P *\<* *.05, ns: non‐significant compared between treatment group and control group](JCMM-22-3005-g002){#jcmm13528-fig-0002}

2.7. Measurement of reactive oxygen species (ROS) activity {#jcmm13528-sec-0009}
----------------------------------------------------------

ROS activity was measured in ccRCC cells from 17 patients with different rs1055259 genotypes (AA = 8, AG = 6, GG = 3) using DCFH‐DA (Beyotime). It is an oxidation‐sensitive fluorescence probe. Cells were seeded in 6‐well plates (1 × 10^5^) and incubated with DCFH‐DA in 37°C for 20 minutes. After washing with PBS, the nuclei were stained by DAPI (Beyotime). The cells were imaged on a Carl Zeiss LSM880 laser scanning confocal microscope (Carl zeiss, Jena, Germany). Quantitative analysis of DCF fluorescence was conducted with Image Pro Plus 6.0 (Media Cybernetics, Silver Spring, MD, USA).

2.8. Cell proliferation and invasion assay {#jcmm13528-sec-0010}
------------------------------------------

Proliferation of ccRCC cells was determined using cell counting kit‐8 (CCK‐8) (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer\'s instructions. Cell invasion measurements were performed with 24‐well Transwell^®^ units (8.0 μm pore; Costar Corning, NY, USA). In brief, cells (1 × 10^3^) in 100 μL were added to each matrigel‐coated insert, and 500 μL of DMEM with 10% FBS was added to the lower chamber, with ROS scavenger N‐acetycysteine (NAC) supplement or not. The plates were incubated at 37°C, 5% CO2 for 24 hours. The non‐invaded cells in the insert were wiped away, and the invaded cells were stained with ponceau. Finally, the images were captured with a phasecontrast microscope (Olympus IX51, Tokyo, Japan). The invaded cells were quantified by counting 10 independent visual fields to determine the average invasion ratio. Each assay was performed in triplicate.

2.9. Statistical analysis {#jcmm13528-sec-0011}
-------------------------

The differences of the demographic and clinical features and frequencies of genotypes in case‐control study were calculated by the chi‐square test (for categorical variables) or Student\'s *t*‐test (for continuous variables). Hardy‐Weinberg equilibrium (HWE) was evaluated by online analytical tools (<https://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The linkage disequilibrium (LD) of candidate SNPs was analysed using HaploView v4.2 (Broad Institute, Cambridge, MA, USA). For the determination of main effect of SNPs, univariate and multivariate logistic regression models were conducted to generate odds ratio (ORs) and corresponding 95% confidence intervals (CIs) with adjustment for possible confounders, that is age, gender, drinking status and so on. All statistical tests were 2‐sided and performed with Statistical Program for Social Sciences (SPSS 16.0, Chicago, IL, USA) and R (<http://www.r-project.org/>). *P *\<* *.05 was considered as statistically significant.

3. RESULTS {#jcmm13528-sec-0012}
==========

3.1. Association of SNPs with ccRCC susceptibility {#jcmm13528-sec-0013}
--------------------------------------------------

rs1537236, rs3814309, rs1109138, rs1055259 and rs5776997 were conformed to HWE in healthy controls, with the *P* value of .417, .695, .510, .728 and .315, respectively. Among the 5 candidate SNPs, rs1055259 variant was significantly associated with an decreased susceptibility of ccRCC. Compared with wild‐type AA, AG and AG + GG genotypes were significantly associated with reduced risk of ccRCC (AG vs AA: adjusted OR = 0.61, 95% CI = 0.43‐0.90, *P *=* *.012; AG + GG vs AA: adjusted OR = 0.59, 95% CI = 0.41‐0.92, *P *=* *.019). In allele comparing model, the rs1055259‐G allele was significantly associated with a decreased susceptibility of ccRCC in comparison with A allele (adjusted OR = 0.72, 95% CI = 0.51‐0.98, *P *=* *.040) (Table [3](#jcmm13528-tbl-0003){ref-type="table-wrap"}).

###### 

Logistic regression analysis of associations between the genotypes of *GSTM3* and ccRCC susceptibility

  Variants                  Genotypes    Cases No. (%) n = 329   Controls No. (%) n = 420   Crude OR (95% CI)   *P* [a](#jcmm13528-note-0005){ref-type="fn"}   Adjusted OR (95% CI)   *P* [b](#jcmm13528-note-0006){ref-type="fn"}
  ------------------------- ------------ ----------------------- -------------------------- ------------------- ---------------------------------------------- ---------------------- ----------------------------------------------
  rs1537236 (HWE = 0.417)   AA           229 (69.6)              281 (66.9)                 1.00 (Reference)                                                   1.00 (Reference)       
  AG                        89 (27.0)    122 (29.0)              0.90 (0.65‐1.24)           .511                0.95 (0.72‐1.34)                               .693                   
  GG                        11 (3.3)     17 (4.0)                0.79 (0.37‐1.73)           .697                0.86 (0.44‐1.89)                               .825                   
  AG + GG                   100 (30.3)   139 (33.0)              0.86 (0.65‐1.20)           .477                0.92 (0.72‐1.35)                               .602                   
  A allele                  547 (83.1)   684 (81.4)              1.00 (Reference)                               1.00 (Reference)                                                      
  G allele                  111 (16.6)   156 (19.6)              0.89 (0.88‐1.16)           .415                0.95 (0.94‐1.23)                               .579                   
  rs3814309 (HWE = 0.695)   CC           179 (54.4)              243 (57.9)                 1.00 (Reference)                                                   1.00 (Reference)       
  CT                        127 (38.6)   151 (36.0)              1.14 (0.84‐1.55)           .436                1.18 (0.89‐1.63)                               .522                   
  TT                        23 (7.0)     26 (6.2)                1.20 (0.66‐2.17)           .546                1.35 (0.79‐2.34)                               .621                   
  CT + TT                   150 (45.6)   177 (42.2)              1.15 (0.86‐1.54)           .373                1.23 (0.91‐1.79)                               .427                   
  C allele                  485 (73.7)   637 (75.8)              1.00 (Reference)                               1.00 (Reference)                                                      
  T allele                  173 (26.3)   203 (24.2)              1.12 (0.89‐1.42)           .368                1.24 (0.91‐1.47)                               .479                   
  rs1109138 (HWE = 0.510)   AA           21 (6.4)                15 (3.6)                   1.00 (Reference)                                                   1.00 (Reference)       
                            AG           85 (25.8)               118 (28.1)                 0.79 (0.48‐1.30)    .370                                           0.84 (0.56‐1.51)       .491
                            GG           223 (67.8)              287 (68.3)                 0.86 (0.55‐1.37)    .559                                           0.91 (0.67‐1.59)       .672
                            AG + GG      308 (93.6)              405 (96.4)                 0.84 (0.54‐1.31)    .493                                           0.90 (0.62‐1.56)       .569
                            A allele     127 (19.3)              148 (17.6)                 1.00 (Reference)                                                   1.00 (Reference)       
                            G allele     531 (80.7)              692 (82.4)                 0.99 (0.79‐1.26)    1.000                                          0.99 (0.80‐1.29)       1.000
  rs1055259 (HWE = 0.728)   AA           252 (76.6)              289 (68.8)                 1.00 (Reference)                                                   1.00 (Reference)       
  AG                        68 (20.7)    120 (28.6)              0.65 (0.46‐0.92)           **.014**            0.61 (0.43‐0.90)                               **.012**               
  GG                        9 (2.7)      11 (2.6)                0.94 (0.38‐2.30)           1.000               0.98 (0.45‐2.41)                               1.000                  
  AG + GG                   77 (23.4)    131 (31.2)              0.67 (0.49‐0.94)           **.021**            0.59 (0.41‐0.92)                               **.019**               
  A allele                  572 (86.9)   698 (83.1)              1.00 (Reference)                               1.00 (Reference)                                                      
  G allele                  86 (13.1)    142 (16.9)              0.74 (0.55‐0.99)           **.043**            0.72 (0.51‐0.98)                               **.040**               
  rs5776997 (HWE = 0.315)   ‐ ‐          234 (71.1)              317 (75.5)                 1.00 (Reference)                                                   1.00 (Reference)       
  ‐ T                       80 (24.3)    93 (22.1)               1.17 (0.83‐1.64)           .429                1.26 (0.96‐1.73)                               .517                   
  TT                        15 (4.6)     10 (2.4)                2.03 (0.90‐4.60)           .099                2.11 (0.93‐4.81)                               .126                   
  ‐ T + TT                  95 (28.9)    103 (24.5)              1.25 (0.90‐1.73)           .183                1.32 (0.95‐1.89)                               .231                   
  ‐ allele                  548 (83.3)   727 (86.5)              1.00 (Reference)                               1.00 (Reference)                                                      
  T allele                  110 (16.7)   113 (13.5)              1.28 (0.96‐1.70)           .107                1.39 (0.99‐1.83)                               .198                   

CI, confidence interval; OR, odds ratio. The significant *P* values were shown in bold.

Chi‐square test for genotype distributions between cases and controls.

Adjusted for age, sex, smoking and drinking status in logistic regress models.
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3.2. Association of SNP rs1055259 genotypes with miR‐556 binding and *GSTM3* expression {#jcmm13528-sec-0014}
---------------------------------------------------------------------------------------

Bioinformatical analyses suggested that rs1055259 was located at miR‐556 binding site, the 3′UTR of *GSTM3*. The A allele was predicted to bind more stably with miR‐556 than G allele, but the binding site in mutant sequence was completely destroyed (Figure [2](#jcmm13528-fig-0002){ref-type="fig"}B). To evaluate the different affinity of A and G allele to miR‐556, 3 luciferase reporter constructs were created. In ccRCC cells transfected with rs1055259‐A allele construct, miR‐556 mimic attenuated the luciferase activity by 45.43% while compared with control group; however, miR‐556 mimic only reduced the luciferase activity by 25.61% in rs1055259‐G allele group (Figure [2](#jcmm13528-fig-0002){ref-type="fig"}C). Antagomir‐miR‐556 increased the luciferase activity by 20.14% in A allele group than that by 14.96% in G allele group (Figure [2](#jcmm13528-fig-0002){ref-type="fig"}D). Intriguingly, CoCl2 treatment reduced the luciferase activity by 31.22% in A allele group and 20.59% in G allele group (Figure [2](#jcmm13528-fig-0002){ref-type="fig"}E). Mutant construct losing the miR‐556 binding site did not represent any obvious change. Based on the above evidences, miR‐556 mimic could knock down *GSTM3* expression in both rs1055259‐A and G allele groups. Antagomir‐miR‐556 increased *GSTM3* expression in A and G allele groups. However, among the 3 conditions (control, miR‐556 mimic, antagomir‐miR‐556), cells carrying A allele construct presented lower luciferase activity than those with G allele. Destruction of the miR‐556 binding site interrupted the effects of miR‐556, antagomir‐miR‐556 or CoCl2 on *GSTM3* expression.

*GSTM3* expression was further compared across cells transfected with miR‐556 in different dose. The data indicated that miR‐556 mimic dose dependently reduced *GSTM3* expression, and antagomir‐miR‐556 increased *GSTM3* expression (Figure [3](#jcmm13528-fig-0003){ref-type="fig"}A‐D). Compared to the control group, CoCl2 decreased *GSTM3* protein level by 76.75%, with an increased miR‐556 level by 3.03‐fold simultaneously (Figure [3](#jcmm13528-fig-0003){ref-type="fig"}E‐G). For in vitro study, CoCl2 is commonly used to mimic a hypoxic environment in inner area of solid tumor. These data suggested that the malignant progression of renal carcinoma might inhibit the *GSTM3* expression via increasing miR‐556 level.

![miR‐556 inhibited *GSTM3* expression in 786‐O cells. (A, B) Western blot assay of *GSTM3* in ccRCC cells transfected with miR‐556 mimic or antagomir‐miR‐556 in different doses. (C, D) Greyscale quantification of the *GSTM3* protein expression levels in ccRCC cells transfected with miR‐556 mimic or antagomir‐miR‐556. (E) 50 μM CoCl2 treatment increased miR‐556 mRNA levels. (G, F) Western blot and quantification plot showed that CoCl2 treatment reduced *GSTM3* protein expression. \**P *\<* *.05, \*\**P *\<* *.01](JCMM-22-3005-g003){#jcmm13528-fig-0003}

3.3. rs1055259 variant reduced ROS activity {#jcmm13528-sec-0015}
-------------------------------------------

To evaluate the biological effect of rs1055259 on *GSTM3* activity in vivo, we measured the ROS activity in ccRCC cells from patients with AA, AG and GG genotypes. As shown in Figure [4](#jcmm13528-fig-0004){ref-type="fig"}, the *GSTM3* activity was obviously different among patients with rs1055259 AA, AG and GG genotypes. The average ROS activity was highest in AA genotype, followed by AG and then lowest in GG genotype (2067.43 ± 117.76, 1310.65 ± 162.07 and 708.51 ± 79.34, respectively). This result suggested that rs1055259 variant, which was related with *GSTM3* expression, indeed reduced ROS activity.

![Reactive oxygen species (ROS) activity in ccRCC primary cells with different genotype of rs1055259. (A) Representative confocal‐microscopy graphs of ROS activity in rs1055259 AA,AG and GG cells incubated with DCFH‐DA (it could be ROS‐oxidized to DCF, which presented green fluorescence). (B) Quantitative analysis of ROS activity in different group. The experiment was repeated at least 3 times. Data were presented as mean ± S.D. Scale bar: 50 μm. \**P *\<* *.05, \*\**P *\<* *.01](JCMM-22-3005-g004){#jcmm13528-fig-0004}

3.4. rs1055259 variant suppressed the proliferation and invasion of ccRCC cells {#jcmm13528-sec-0016}
-------------------------------------------------------------------------------

It has been proven that *GSTM3* is a tumour suppressor in ccRCC.[8](#jcmm13528-bib-0008){ref-type="ref"} To confirm the relationship between rs1055259 and progression of ccRCC, we detected the proliferation and invasion of ccRCC cells with AA, AG and GG genotypes under NAC+/− conditions. The data showed that invasion cells trans‐micropore filtration membranes per visual field were the most in AA group, then AG and GG groups (169.52 ± 17.68, 130.76 ± 9.91 and 115.29 ± 19.80, respectively). While the ROS scavenger‐NAC was added in the concentration of 1 mmol/L, the number of invasion cells was obviously decreased by 18.17% in AA group and 23.12% in AG group, but no significant change in GG group (Figure [5](#jcmm13528-fig-0005){ref-type="fig"}A,C). Similarly, the cell viability for proliferation ability investigation in AA group was the highest (standardized as 100%) than AG and GG groups (64.50% and 55.39%, respectively). In addition to NAC, the cell viability was notably reduced by 43.52%, 36.43% and 30.71% in AA, AG and GG groups, respectively (Figure [5](#jcmm13528-fig-0005){ref-type="fig"}B). Taken together, rs1055259 variant substantially suppressed the proliferation and invasion of ccRCC cells. NAC inhibited the ROS activity and thus repressed the progression of ccRCC cells.

![The proliferation and invasion of ccRCC primary cells with different genotype after reactive oxygen species (ROS) scavenger NAC (5 mmol/L) treatment or not. (A) Representative graphs for the invasion assay of rs1055259 AA,AG and GG cells with NAC treatment or not. (B) The percentages of cell viability in CCK‐8 proliferation assay. (C) Quantitative analysis of invasion cells in different groups. The experiment was repeated at least 3 times. Data were presented as mean ± SD. Scale bar: 50 μm. \**P *\<* *.05](JCMM-22-3005-g005){#jcmm13528-fig-0005}

4. DISCUSSION {#jcmm13528-sec-0017}
=============

In the present study, we studied the genetic effects of SNPs in 3′UTR of *GSTM3* on the progression of ccRCC. Five candidate SNPs were MALDI‐TOF MS genotyped in 329 ccRCC patients and 420 healthy controls. A significant association between rs1055259 and decreased ccRCC susceptibility was identified. Variant G allele of rs1055259 enhanced *GSTM3* expression via affecting the binding of miR‐556 and 3′UTR, resulting in low ROS level, and further suppressing the proliferation and invasion of ccRCC cells (Figure [6](#jcmm13528-fig-0006){ref-type="fig"}).

![Schematic diagram for the potential functions of rs1055259 in *GSTM3* expression and progression of ccRCC. Variant G allele of rs1055259 might elevate *GSTM3* expression by affecting the binding of miR‐556 and 3′UTR of *GSTM3* gene, resulting in low reactive oxygen species (ROS) level and high thiol level, and further suppress the proliferation and invasion of ccRCC cells](JCMM-22-3005-g006){#jcmm13528-fig-0006}

rs1055259 is located at the 3′UTR of *GSTM3* and predicted in a miR‐556 binding site, with transcription regulatory potential. When allele A changes to G, the secondary folding structure of mRNA changed (Figure [S1](#jcmm13528-sup-0001){ref-type="supplementary-material"}); the affinity score of theoretical mRNA: miRNA duplex is strikingly decreased, and the binding site is lost. These analysis data acquired using online bioinformatical software rSNP and SNPinfo confirmed the significance of this locus in transcriptional regulation. According to the evidences shown in Figure [2](#jcmm13528-fig-0002){ref-type="fig"} and [3](#jcmm13528-fig-0003){ref-type="fig"}, rs1055259 A \> G change increased the transcriptional activity, affected the miRNA binding and enhanced *GSTM3* expression. To the best of our knowledge, the functional polymorphism‐rs1055259 has not been reported in other investigations. This is the first study to demonstrate the potential function of rs1055259 in *GSTM3* expression and ccRCC development.

Another intriguing finding was that rs1055259 might be related to ROS activity, by fine tuning the *GSTM3* expression. As is known to all, cytosolic glutathione S‐transferases (GSTs) are members of phase II metabolic isozymes super family. They protect cells against electrophilic damage via catalysing the conjugation of ROS and glutathione.[9](#jcmm13528-bib-0009){ref-type="ref"}, [10](#jcmm13528-bib-0010){ref-type="ref"} Dysfunction of GSTs has been implicated in the progression of RCC, because of the defect of anti‐oxidant capacity.[11](#jcmm13528-bib-0011){ref-type="ref"} Our study showed that the ROS activity (reflected by DCF immunofluorescence) was highest in ccRCC cells with rs1055259 AA genotype than AG and GG genotypes. However, rs1055259 variant was proven associated with *GSTM3* expression. Namely rs1055259 might modulate the ROS activity via elevating *GSTM3* expression. Thus, the subjects carrying A allele are more prone to ccRCC because their ROS activity tends to be higher against those with G allele.

Generous studies revealed that epigenetic inactivation of *GSTM3* or low *GSTM3* expression correlated with tumorigenesis and advanced AJCC stage of cancer.[12](#jcmm13528-bib-0012){ref-type="ref"}, [13](#jcmm13528-bib-0013){ref-type="ref"} These reports, together with our previously study,[7](#jcmm13528-bib-0007){ref-type="ref"} suggested that *GSTM3* might function as a suppressor in tumour progression. Elevated ROS activity also played an important role in cancer cell survival and development.[14](#jcmm13528-bib-0014){ref-type="ref"} Thus, we detected the relationship between rs1055259, ROS activity and ccRCC development. In transwell assay, we found that the invasion cells per visual field were the most in AA group and then AG and GG groups. After ROS scavenger‐NAC was added, the numbers of invasion cells were obviously decreased. Similarly, the cell viability in AA group was higher than AG and GG group. With NAC+, the cell viability was notably reduced by more than 30%. Taken together, rs1055259 variant substantially suppressed the proliferation and invasion of ccRCC cells. NAC inhibited the ROS activity and thus repressed the progression of ccRCC cells. It suggested that *GSTM3* might act as a tumour suppressor via ROS activity regulation.

There were several limitations in this study: (1) because all the participants were collected from eastern Han Chinese population, the association between *GSTM3* variants and ccRCC risk might not be generalized to overall ethnic groups. (2) The large cohort, multi‐centre studies about association between rs1055259 and ccRCC risk should be performed to generate more potent statistical powers. (3) ccRCC is a complicated process. The genetic variation and the effects of tumour environmental cues such as oxygen variability might contribute to the tumour heterogeneity and development. The producing and neutralizing of ROS are pivotal in tumour development because many factors, lipids and nucleic acids are downstream targets of ROS.[15](#jcmm13528-bib-0015){ref-type="ref"}, [16](#jcmm13528-bib-0016){ref-type="ref"}, [17](#jcmm13528-bib-0017){ref-type="ref"} Several studies revealed that unregulated and augmented ROS could initiate redox‐linked signalling responses and irreversible injuries in RCC.[18](#jcmm13528-bib-0018){ref-type="ref"}, [19](#jcmm13528-bib-0019){ref-type="ref"} Moreover, changes of cellular redox balance in RCC might also be associated with alterations of glutathione S‐transferase (GST) expression and phenotype.[18](#jcmm13528-bib-0018){ref-type="ref"} Therefore, it is necessary to clarify underlying mechanisms between the important anti‐oxidant enzyme‐GSTM3 in ccRCC,[7](#jcmm13528-bib-0007){ref-type="ref"}, [8](#jcmm13528-bib-0008){ref-type="ref"} thiol level, ROS activity and redox signalling responses. The further investigations should be carried out.

In summary, we demonstrated that rs1055259 in *GSTM3* 3′UTR affected the miR‐556 binding and *GSTM3* expression in ccRCC for the first time. The G allele of rs1055259 predisposes hosts to down‐regulated *GSTM3* and reduced ccRCC susceptibility. rs1055259 variant genotype was a significant genetic protect factor. These findings will be helpful in diagnosis prediction and surveillance of ccRCC, as well as in the advancement of targeted therapy for this renal malignancy. The current study also indicated that it warranted further investigations of *GSTM3* expression in ccRCC.
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